{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:00:53Z","timestamp":1793912453936,"version":"4.8.0"},"reference-count":15,"publisher":"Baishideng Publishing Group Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Gastroenterol"],"abstract":"BACKGROUND<\/jats:p>\n Filgotinib, a JAK1-preferential inhibitor, has demonstrated efficacy in pivotal clinical trials for moderate-to-severe ulcerative colitis (UC), leading to regulatory approvals. While emerging real-world studies provide short-term effectiveness data, comprehensive long-term evidence\u2014particularly beyond 6 months\u2014remains scarce, especially in heavily biologic-experienced populations.<\/jats:p>\n AIM<\/jats:p>\n To evaluate the 12-month effectiveness, safety, and predictors of response to filgotinib in a real-world cohort of patients with moderate-to-severe UC treated across multiple centers in Andalusia, Spain.<\/jats:p>\n METHODS<\/jats:p>\n This multicenter, ambispective observational study (FILGUITO registry) included 104 adults with moderate-to-severe UC initiating filgotinib therapy. Demographic, clinical, laboratory, and endoscopic data were collected at baseline and at 8 weeks, 6 months, and 12 months. Effectiveness outcomes included clinical remission (Mayo partial score < 3 with no subscore > 1 and no rectal bleeding), clinical-biochemical remission (clinical remission plus fecal calprotectin < 250 \u03bcg\/g), and steroid-free remission (clinical remission with no corticosteroid courses from week 8). Safety was assessed through adverse event monitoring.<\/jats:p>\n RESULTS<\/jats:p>\n The median age was 40.7 years (IQR: 29.5-51.0), with 56.7% male patients. The majority (79.8%) had prior advanced therapy exposure, with a median of 1 prior biologic (IQR: 1-3). Clinical remission rates were 60.8% at 8 weeks, 61.4% at 6 months, and 60.3% at 12 months (all P < 0.001 vs baseline). Clinical-biochemical remission reached 33.0%, 38.6%, and 31.0% at the same timepoints. Steroid-free remission was achieved in 60.0% at 6 months and 56.9% at 12 months. Median fecal calprotectin decreased significantly from 2000 \u03bcg\/g at baseline (IQR: 755.8-2392.5) to 153 \u03bcg\/g at 12 months (IQR: 21.3-569.0, P < 0.001). Treatment discontinuation occurred in 22.1% of patients by 12 months, primarily due to lack of response. Serious adverse events were rare (2.8%), with a favorable safety profile. Patients with only one prior biologic showed higher remission rates compared to those with multiple prior treatments.<\/jats:p>\n CONCLUSION<\/jats:p>\n Filgotinib demonstrates sustained clinical effectiveness and a favorable safety profile over 12 months in a real-world UC cohort with extensive prior biologic exposure. Effectiveness is optimized at earlier treatment lines, though meaningful benefit persists in heavily pre-treated populations.<\/jats:p>","DOI":"10.3748\/wjg.v32.i6.115941","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:53:43Z","timestamp":1770015223000},"source":"Crossref","is-referenced-by-count":3,"title":["Long-term clinical outcomes with filgotinib in ulcerative colitis: 12-month results from the FILGUITO study"],"prefix":"10.3748","volume":"32","author":[{"given":"Antonio M","family":"Caballero-Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Trigo-Salado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Su\u00e1rez-Toribio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Mar","family":"Mart\u00edn-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J","family":"Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Vald\u00e9s-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Pallar\u00e9s-Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Trapero-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Olmedo-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bail\u00f3n-Gaona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Benitez Cantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"S\u00e1ez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Hern\u00e1ndez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx008"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i35.3942"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18158"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad187"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.082909"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-022-00439-w"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12704"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2024-11-1"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18406"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaf030"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.1023"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00148"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v32\/i6\/115941.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v32\/i6\/115941.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:53:58Z","timestamp":1770015238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v32\/i6\/115941.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":15,"journal-issue":{"issue":"6"},"alternative-id":["115941"],"URL":"https:\/\/doi.org\/10.3748\/wjg.v32.i6.115941","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}